Clinical trials: HIV-2 Infection
HIV1 Infection, HIV 2 Infection
A Study to Evaluate the Performance, and Usability of TruPlex HIV/HepB/Syphilis Rapid Test
To evaluate the clinical performance of each analyte (HIV, HBsAg, and Syphilis) on the TruPlex HIV/HepB/Syphilis Rapid Test (TruPlex Test) using capillary blood (fingerstick), EDTA whole blood, EDTA-plasma, and SST-serum samples…
- Conditions
- HIV1 Infection, HIV 2 Infection, Syphilis Infection, Hepatitis B Infection
- Trial name
- NCT07569913
- Testing
- TruPlex HIV/HepB/Syphilis Rapid Test
- Where
- Australia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
HIV Infections
Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients
The purpose of this study is to evaluate the efficacy of raltegravir with optimized background therapy (OBT) in multiple-experienced HIV infected patients, measured by the proportion of patients with undetectable viral load and…
- Trial name
- NCT01190124
- Volunteers
- 151 people
- Sponsor
- Doroana, Maria Manuela, M.D.
HIV II Infection
Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects
Multicenter, single-arm, open-label clinical trial to evaluate the efficacy, the safety and the tolerability of 50 mg dolutegravir once daily (q.d.) given in combination with 2 NRTIs backbone in HIV-2 positive, treatment-naïve…
- Trial name
- NCT03224338
- Testing
- Dolutegravir 50 mg
- Where
- 6 sites in Portugal
- Volunteers
- 30 people
- Sponsor
- Blueclinical, Ltd.
HIV-2 Infection
First-Line Treatment for HIV-2
FIT-2 is a multi-country, phase IIb, randomized, non-comparative study, carried out in West Africa (Côte d'Ivoire, Burkina Faso, Senegal, Togo).
- Trial name
- FIT-2 (NCT02150993)
- Testing
- Tenofovir + Emtricitabine or Lamivudine + Zidovudine, Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir, Tenofovir + Emtricitabine or Lamivudine + Raltegravir
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 210 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-2 Infection
Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients
The HIV-2 is less common ie 1-2 million people in West Africa. HIV-2 does have the same sensitivity to antiretroviral treatment (ART) compared to HIV-1.
- Trial name
- VIH-2 (NCT01605890)
- Testing
- emtricitabine / tenofovir disoproxil fumarate / raltegravir .
- Where
- France
- Volunteers
- 30 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections, HIV-1-infection
Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV
Combination antiretroviral therapy (cART) blocks intracellular human immunodeficiency virus (HIV) replication in CD4+ T-lymphocytes, but fails to eliminate latent HIV infected CD4+ T-lymphocytes.
- Conditions
- HIV Infections, HIV-1-infection, HIV-2 Infection
- Trial name
- EX VIVO (NCT05215704)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Erasmus Medical Center
HIV-1 Infection
Probiotic Visbiome for Inflammation and Translocation in HIV II
Modern antiretroviral therapy (ART) has transformed the clinical care and lived experience of HIV infection. However, increased rates of adverse health conditions that are related to immune activation, such as cardiovascular…
- Trial name
- PROOV IT II (NCT02441231)
- Testing
- Visbiome
- Where
- 2 sites in Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
HIV-2 Infection
Cohorte Nationale VIH-2
The HIV2 study is an open cohort of prospective, multicentric, national observation. The main objective is to study HIV-2 infection in adult patients followed in France.
- Trial name
- ANRS CO VIH2 (NCT04658329)
- Testing
- Antiretroviral
- Where
- 29 sites in France
- Volunteers
- 1,185 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-2 Infection
An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
There is a critical need for safe and effective antiretroviral treatment (ART) regimens for HIV-2 infection. This is especially true in West Africa, where the vast majority of the 1-2 million individuals infected with HIV-2 live…
- Trial name
- Stribild HIV-2 (NCT02180438)
- Testing
- Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks
- Where
- Senegal
- Volunteers
- 30 people
- Sponsor
- University of Washington
HIV Infections, HIV-1-infection
A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands
A prospective non-interventional cohort study at Erasmus MC of adult chronic HIV infected patients of ≥18 years of age who initiate antiretroviral therapy in routine care.
- Conditions
- HIV Infections, HIV-1-infection, HIV-2 Infection
- Trial name
- CHRONO (NCT04888754)
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Erasmus Medical Center
HIV I Infection, HIV-2 Infection
Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol
The objective of this study is the collection and testing of clinical samples to determine the clinical performance of the Access HIV Ag/Ab Combo assay on the DxI 9000 Access Immunoassay Analyzer
- Trial name
- HIV-EU-11-18 (NCT04971343)
- Testing
- Access HIV_blood donor, Access HIV_Hospitalized patient, Access HIV_known HIV-1 antibody positives
- Where
- 6 sites in France
- Volunteers
- 8,650 people
- Sponsor
- Beckman Coulter, Inc.
HIV 1 Infection, HIV 2 Infection
A Study to Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test
The objectives of this study are as follows: To evaluate the clinical performance of the TruPlex test using capillary blood, EDTA whole blood, EDTA plasma, and SST serum samples collected by trained operators in point-of-care…
- Conditions
- HIV 1 Infection, HIV 2 Infection, Syphilis Infection, Hepatitis B Infection
- Trial name
- NCT07563309
- Testing
- TruPlex HIV/HepB/Syphilis Rapid Test
- Where
- 3 sites in South Africa
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
Acquired Immunodeficiency Syndrome, Blood Donors
Retrovirus Epidemiology Donor Study-II (REDS-II)
To conduct epidemiological, laboratory, and survey research on volunteer blood donors within the United States to ensure the safety and availability of the United States' blood supply.
- Conditions
- Acquired Immunodeficiency Syndrome, Blood Donors, Blood Transfusion, HIV Infections
- Trial name
- NCT00097006
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
HIV-2 Infection
RESIST-2: 2nd-line ART for HIV-2 Infection
Prospective, longitudinal, open label, HIV-2 viral load and antiretroviral resistance informed 2nd-line ARV implementation study.
- Trial name
- RESIST-2 (NCT03394196)
- Testing
- HIV-2 Genotypic Drug Resistance Testing using DBS, 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )
- Where
- 2 sites in Senegal
- Volunteers
- 152 people
- Sponsor
- University of Washington
Acquired Immunodeficiency Syndrome, Blood Donors
Retrovirus Epidemiology Donor Study I (REDS I)
To conduct a multicenter epidemiologic study of the human retroviruses HIV-1, HIV-2, HTLV-I, and HTLV-II in volunteer blood donors from areas of the United States that were reportedly at high and medium or low risk for HIV.
- Conditions
- Acquired Immunodeficiency Syndrome, Blood Donors, Blood Transfusion, HIV Infections
- Trial name
- NCT00005278
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)